Latest Emergent Biosolutions (EBS) Headlines
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:10AM CDT
Emergent had a strong quarter with both revenues and earnings coming above expectations.
Emergent BioSolutions (EBS) Soars: Stock Rises 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:51AM CDT
Emergent BioSolutions, Inc. was a big mover last session, as its shares rose nearly 9% on the day.
3 Biotech Stocks Spiking on Big Volume
at The Street - Mon Mar 10, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.
Emergent BioSolutions reports 32% rise in GAAP net income & 11% in revenues in 2013
M2 - Fri Mar 07, 4:16AM CST
US-based pharmaceutical company Emergent BioSolutions (NYSE:EBS) disclosed on Thursday a GAAP net income of USD31.1m (USD0.86 per basic share) for the full year ended 31 December 2013.
VALNEVA Announces a New Research Agreement and Transfer of an Existing Commercial Agreement to Emergent BioSolutions for the Development of Vaccines in the EB66(R) Cell Line
Thomson Reuters ONE - Fri Mar 07, 12:30AM CST
Valneva Announces a New Research Agreement and Transfer of an Existing Commercial Agreement to Emergent BioSolutions for the Development of Vaccines in the EB66(R) Cell Line
Emergent BioSolutions Reports Financial Results for 2013
Business Wire - Thu Mar 06, 3:01PM CST
--Product sales of $257.9 million, up 19%
Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:54AM CST
Synta Pharmaceuticals Corp. (SNTA) saw a big move last session, reversing the recent trend for SNTA as the stock is now up around 8.4% in the past one-month time frame.
Biodel enters into commercial manufacturing agreement for Glucagon Rescue Product with Emergent BioSolutions
M2 - Thu Mar 06, 5:05AM CST
Biopharmaceutical company Biodel (NasdaqCM:BIOD) revealed on Wednesday the launch of another agreement for its Glucagon Emergency Management (GEM) development and manufacturing programme with Cangene bioPharma (Emergent BioSolutions).
Biodel Announces Commercial Manufacturing Agreement With Emergent BioSolutions for Glucagon Rescue Product
GlobeNewswire - Wed Mar 05, 3:00PM CST
Biodel Inc. (Nasdaq:BIOD) today announced another development in its Glucagon Emergency Management (GEM) development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions ("Emergent"). Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed.
Celldex Posts Narrower-Than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 10:30AM CST
Celldex' loss narrows in Q4
Celldex Therapeutics (CLDX) in Focus: Stock Tumbles 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:56AM CST
Celldex Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 10% on the day.
Dendreon Corp. (DNDN) Soars: Stock Rises 14.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:51AM CST
Dendreon Corp. was a big mover last session, as its shares rose nearly 15% on the day.
EU Review for The Medicines Co.'s Oritavancin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:55PM CST
The Medicines Co.'s marketing authorization application for oritavancin accepted by the European Medicines Agency (EMA) for review.
Emergent BioSolutions to Release Fourth Quarter and Full Year 2013 Financial Results and Conduct a Conference Call on March 6, 2014
Business Wire - Mon Mar 03, 6:00AM CST
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the fourth quarter and full year 2013 on Thursday, March 6, 2014, after market close.
Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.
Zacks Investment Ideas feature highlights: Emergent Biosolutions, Horizon Pharma and Medivation
PR Newswire - Fri Feb 28, 8:30AM CST
Today, Zacks Investment Ideas feature highlights Features: Emergent Biosolutions (NYSE:EBS-Free Report), Horizon Pharma Inc (Nasdaq:HZNP-Free Report) and Medivation (Nasdaq:MDVN-Free Report).
bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:51AM CST
bluebird bio, Inc. (BLUE) was a big mover last session, as its shares surged over 7% on the day.
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 8:10AM CDT
Emergent had a strong quarter with both revenues and earnings coming above expectations.
Emergent BioSolutions (EBS) Soars: Stock Rises 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 7:51AM CDT
Emergent BioSolutions, Inc. was a big mover last session, as its shares rose nearly 9% on the day.
3 Biotech Stocks Spiking on Big Volume
at The Street - Mon Mar 10, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:00AM CST
Kamada has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy. A key reason for this move has been the positive trend in the earnings estimate revisions picture.
Emergent BioSolutions reports 32% rise in GAAP net income & 11% in revenues in 2013
M2 - Fri Mar 07, 4:16AM CST
US-based pharmaceutical company Emergent BioSolutions (NYSE:EBS) disclosed on Thursday a GAAP net income of USD31.1m (USD0.86 per basic share) for the full year ended 31 December 2013.
VALNEVA Announces a New Research Agreement and Transfer of an Existing Commercial Agreement to Emergent BioSolutions for the Development of Vaccines in the EB66(R) Cell Line
Thomson Reuters ONE - Fri Mar 07, 12:30AM CST
Valneva Announces a New Research Agreement and Transfer of an Existing Commercial Agreement to Emergent BioSolutions for the Development of Vaccines in the EB66(R) Cell Line
Emergent BioSolutions Reports Financial Results for 2013
Business Wire - Thu Mar 06, 3:01PM CST
--Product sales of $257.9 million, up 19%
Weakness Seen in Synta Pharmaceuticals (SNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:54AM CST
Synta Pharmaceuticals Corp. (SNTA) saw a big move last session, reversing the recent trend for SNTA as the stock is now up around 8.4% in the past one-month time frame.
Biodel enters into commercial manufacturing agreement for Glucagon Rescue Product with Emergent BioSolutions
M2 - Thu Mar 06, 5:05AM CST
Biopharmaceutical company Biodel (NasdaqCM:BIOD) revealed on Wednesday the launch of another agreement for its Glucagon Emergency Management (GEM) development and manufacturing programme with Cangene bioPharma (Emergent BioSolutions).
Biodel Announces Commercial Manufacturing Agreement With Emergent BioSolutions for Glucagon Rescue Product
GlobeNewswire - Wed Mar 05, 3:00PM CST
Biodel Inc. (Nasdaq:BIOD) today announced another development in its Glucagon Emergency Management (GEM) development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions ("Emergent"). Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed.
Celldex Posts Narrower-Than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 10:30AM CST
Celldex' loss narrows in Q4
Celldex Therapeutics (CLDX) in Focus: Stock Tumbles 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:56AM CST
Celldex Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 10% on the day.
Dendreon Corp. (DNDN) Soars: Stock Rises 14.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:51AM CST
Dendreon Corp. was a big mover last session, as its shares rose nearly 15% on the day.
EU Review for The Medicines Co.'s Oritavancin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:55PM CST
The Medicines Co.'s marketing authorization application for oritavancin accepted by the European Medicines Agency (EMA) for review.
Emergent BioSolutions to Release Fourth Quarter and Full Year 2013 Financial Results and Conduct a Conference Call on March 6, 2014
Business Wire - Mon Mar 03, 6:00AM CST
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the fourth quarter and full year 2013 on Thursday, March 6, 2014, after market close.
Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.
Zacks Investment Ideas feature highlights: Emergent Biosolutions, Horizon Pharma and Medivation
PR Newswire - Fri Feb 28, 8:30AM CST
Today, Zacks Investment Ideas feature highlights Features: Emergent Biosolutions (NYSE:EBS-Free Report), Horizon Pharma Inc (Nasdaq:HZNP-Free Report) and Medivation (Nasdaq:MDVN-Free Report).
bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 7:51AM CST
bluebird bio, Inc. (BLUE) was a big mover last session, as its shares surged over 7% on the day.
